pharma news

Mar 24, 2020

Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020.  The company has been acquirin...

Mar 19, 2020

Sage Therapeutics seeking out to save flunked depression drug  Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allost...

Mar 17, 2020

Moderna announces dozing of first patient with its mRNA1273 vaccine The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clin...

Mar 12, 2020

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)  The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...

Mar 11, 2020

Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease - ILD – a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditi...

Mar 05, 2020

Killing brain tumors with the help of CAR-T CAR-T cell therapy is a technique which involves modifying patients' T cells to aim proteins associated with cancer that have revolutionized some of the blood cancers treatment. However, the technique has so far shown low potential in solid tumors like aggressive brain...

Mar 03, 2020

Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. By acquiring Forty Seven – named after its lead molecule - CD47 tumor cell protein - Gilead will acquire its lead candidate, Magrolimab, adding value to its ...

Feb 25, 2020

Formerly known as eptinezumab, Lundbeck’s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine.  With the gree...

Feb 20, 2020

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market. Ruxoliti...

Feb 13, 2020

J&J collaborates with BARDA to accelerate coronavirus vaccine program Johnson & Johnson has collaborated with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to produce a vaccine against novel coronavirus. J&J is attempting to pool money and resources with BARDA in order to qu...